These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. [Are anti-TNFAb indicated in systemic necrotizing vasculitides?]. Guillevin L Rev Med Interne; 2005 Oct; 26(10):769-70. PubMed ID: 16039017 [No Abstract] [Full Text] [Related]
12. Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Should Type of ANCA Guide the Treatment? Tesar V; Hruskova Z Clin J Am Soc Nephrol; 2020 Oct; 15(10):1519-1521. PubMed ID: 32471814 [No Abstract] [Full Text] [Related]
13. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. Jayne D; Rasmussen N; Andrassy K; Bacon P; Tervaert JW; Dadoniené J; Ekstrand A; Gaskin G; Gregorini G; de Groot K; Gross W; Hagen EC; Mirapeix E; Pettersson E; Siegert C; Sinico A; Tesar V; Westman K; Pusey C; N Engl J Med; 2003 Jul; 349(1):36-44. PubMed ID: 12840090 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH; Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953 [TBL] [Abstract][Full Text] [Related]
15. Necrotizing vasculitis--a 2009 update. Sharaf PH; Yazici Y Bull NYU Hosp Jt Dis; 2009; 67(3):303-5. PubMed ID: 19852754 [TBL] [Abstract][Full Text] [Related]
16. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR; Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829 [TBL] [Abstract][Full Text] [Related]
17. [New aspects in ANCA-associated vasculitides]. Lamprecht P Med Klin (Munich); 2004 Sep; 99(9):518-22. PubMed ID: 15372181 [TBL] [Abstract][Full Text] [Related]
18. S3. Rituximab for ANCA-associated vasculitides: the French experience. Charles P; Guillevin L Presse Med; 2013 Apr; 42(4 Pt 2):534-6. PubMed ID: 23453207 [No Abstract] [Full Text] [Related]
19. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368 [TBL] [Abstract][Full Text] [Related]
20. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Mukhtyar C; Flossmann O; Hellmich B; Bacon P; Cid M; Cohen-Tervaert JW; Gross WL; Guillevin L; Jayne D; Mahr A; Merkel PA; Raspe H; Scott D; Witter J; Yazici H; Luqmani RA; Ann Rheum Dis; 2008 Jul; 67(7):1004-10. PubMed ID: 17911225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]